When eliminating the chronic form of myeloid leukemia, the dosage of the drug will depend on the stage of pathology. In the treatment of chronic stage, 400 mg of medicine per day is required; at the time of acceleration or blast crisis, the daily dose is 600 mg. For a day, the medicine is used once, along with the food, the capsule should be filled with water (a full glass). The course of therapy is rather long, it is necessary to achieve and further support hematological and remission remission.
If there are no negative reactions, and in addition expressed thrombocytopathic or neutropenia (which are not associated with the underlying disease), under the following conditions it is permitted to increase the dosage of drugs: if the pathology progresses (at any time); if there is no hematologic response after more than 3 months of therapy; if the previously hematologic reaction was lost.
People with a chronic stage of pathology are allowed to increase the daily dosage to 600 mg. During the blast crisis or the stage of acceleration, it is allowed to increase the daily dose to 800 mg (divided by 2 administration - 400 mg).
During the treatment period, sometimes a correction of the chosen dosage is required (this depends on the dynamics of changes in the blood of platelet counts with neutrophils). If the patient develops thrombocytopenia or neutropenia, it is necessary to cancel the drug for a while or to lower its dosage (the choice of option depends on the severity of the side effects).
During the treatment of the chronic stage of the chronic form of myeloid leukemia (with an initial daily dosage of 400 mg), if the neutrophil count drops to less than 1.0x109 / l, and the platelet count drops to less than 50x109 / l, drug withdrawal is required. Renewal of treatment is impossible until the neutrophil count does not exceed 1.5x109 / l, and platelets - the figure of 75x109 / l. Under these conditions, it is allowed to continue therapy (daily dosage of LS is 400 mg). If the platelet count or neutrophil counts decrease again, the drug should be canceled again, wait for the recovery of the required level of indicators, and then resume treatment with a daily dosage of 300 mg.
If at the stages of acceleration or blast crisis (with an initial daily dose of 600 mg) the neutrophil count falls below 0.5x109 / l, and the platelet count drops to less than 10x109 / l, and this occurs after a minimum of 1 month of treatment with Imatib, It is required to clarify whether cytopenia develops because of leukemia (bone marrow biopsy or aspiration). In the absence of the above-mentioned connection, it is necessary to reduce the daily dosage of LS to 400 mg. If cytopenia continues for the next 2 weeks, the daily dosage should be reduced to 300 mg. With continued development of cytopenia during the next 4 weeks (with unconfirmed association with leukemia), it is required to cancel the drug until the neutrophil level exceeds 1x109 / l, and the platelet count does not exceed 20x109 / l. Renewal therapy should be taken with a daily dosage of 300 mg.
In malignant metastatic tumors (stromal) in the gastrointestinal tract, the daily dosage is 400-600 mg.
For children, the daily dose is 400 or 600 mg, which must be taken in 1 session or twice (in the morning, and also in the evening).